CoChat

Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Objective: (1) This study aims to identify distinct serum metabolites in gastric cancer patients compared to healthy individuals, providing valuable insights into postoperative efficacy evaluation and monitoring of gastric cancer recurrence; (2) Methods: Serum samples were collected from 15 healthy individuals, 16 gastric cancer patients before surgery, 3 months after surgery, 6 months after surgery, and 15 gastric cancer recurrence patients. T-test and analysis of variance (ANOVA) were performed to screen 489 differential metabolites between the preoperative group and the healthy control group. Based on the level of the above metabolites in the recurrence, preoperative, three-month postoperative, and six-month postoperative groups, we further selected 18 significant differential metabolites by ANOVA and partial least squares discriminant analysis (PLS-DA). The result of hierarchical clustering analysis about the above metabolites showed that the samples were regrouped into the tumor-bearing group (comprising the original recurrence and preoperative groups) and the tumor-free group (comprising the original three-month postoperative and six-month postoperative groups). Based on the results of PLS-DA, 7 differential metabolites (VIP > 1.0) were further selected to distinguish the tumor-bearing group and the tumor-free group. Finally, the results of hierarchical clustering analysis showed that these 7 metabolites could well identify gastric cancer recurrence; (3) Results: Lysophosphatidic acids, triglycerides, lysine, and sphingosine-1-phosphate were significantly elevated in the three-month postoperative, six-month postoperative, and healthy control groups, compared to the preoperative and recurrence groups. Conversely, phosphatidylcholine, oxidized ceramide, and phosphatidylglycerol were significantly reduced in the three-month postoperative, six-month postoperative, and healthy control groups compared to the preoperative and recurrence groups. However, these substances did not show significant differences between the preoperative and recurrence groups, nor between the three-month postoperative, six-month postoperative, and healthy control groups; (4) Conclusions: Our findings demonstrate the presence of distinct metabolites in the serum of gastric cancer patients compared to healthy individuals. Lysophosphatidic acid, triglycerides, lysine, sphingosine-1-phosphate, phosphatidylcholine, oxidized ceramide, and phosphatidylglycerol hold potential as biomarkers for evaluating postoperative efficacy and monitoring recurrence in gastric cancer patients. These metabolites exhibit varying concentrations across different sample categories.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-023-11786-2

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Visualization of Total Ion Chromatograms and PCA Plots in Positive and Negative Ion Modes. (a) The total ion chromatogram of the preoperative group in positive ion mode; (b) The total ion chromatogram of the healthy control group in positive ion mode; (c) The total ion chromatogram of the preoperative group in negative ion mode; (d) the total ion chromatogram of the healthy control group in negative ion mode; (e) The PCA plot in positive ion mode; (f) The PCA plot in negative ion mode
Fig. 1 Visualization of Total Ion Chromatograms and PCA Plots in Positive and Negative Ion Modes. (a) The total ion chromatogram of the preoperative group in positive ion mode; (b) The total ion chromatogram of the healthy control group in positive ion mode; (c) The total ion chromatogram of the preoperative group in negative ion mode; (d) the total ion chromatogram of the healthy control group in negative ion mode; (e) The PCA plot in positive ion mode; (f) The PCA plot in negative ion modeCC BY · PubMed Central
Fig. 2 Comparative T-test and Variance Analysis Plots in Positive and Negative Ion Modes. (a) The T-test analysis plot in positive ion mode; (b) T-test analysis plot in negative ion mode. The y-axis represents the magnitude of P-values, where larger values indicate smaller P-values, and the x-axis represents the relative abundance of each metabolite. In the plot, the purple area represents the metabolites with P-values < 0.01; (c) The variance analysis plot of differential metabolites. The red area in the plot represents the metabolites with P-values < 0.01
Fig. 2 Comparative T-test and Variance Analysis Plots in Positive and Negative Ion Modes. (a) The T-test analysis plot in positive ion mode; (b) T-test analysis plot in negative ion mode. The y-axis represents the magnitude of P-values, where larger values indicate smaller P-values, and the x-axis represents the relative abundance of each metabolite. In the plot, the purple area represents the metabolites with P-values < 0.01; (c) The variance analysis plot of differential metabolites. The red area in the plot represents the metabolites with P-values < 0.01CC BY · PubMed Central
Fig. 3 PLS-DA Plot, VIP Score Plot, and Clustering Analysis of 18 Differential Metabolites. (a) PLS-DA plot; (b) VIP (Variable Importance in Projection) score plot for the selected differential metabolites with VIP > 1.2; (c) Hierarchical clustering analysis of the 18 differential metabolites. The color scale represents the relative abundance of metabolites, with red indicating higher abundance, deep blue indicating lower abundance, and light blue indicating zero abundance. The right side of the figure shows the mass-to-charge ratio (m/z) of each metabolite, while the dendrogram on the left and top represents the clustering results of the differential metabolites. The sample numbers are shown at the bottom of the figure
Fig. 3 PLS-DA Plot, VIP Score Plot, and Clustering Analysis of 18 Differential Metabolites. (a) PLS-DA plot; (b) VIP (Variable Importance in Projection) score plot for the selected differential metabolites with VIP > 1.2; (c) Hierarchical clustering analysis of the 18 differential metabolites. The color scale represents the relative abundance of metabolites, with red indicating higher abundance, deep blue indicating lower abundance, and light blue indicating zero abundance. The right side of the figure shows the mass-to-charge ratio (m/z) of each metabolite, while the dendrogram on the left and top represents the clustering results of the differential metabolites. The sample numbers are shown at the bottom of the figureCC BY · PubMed Central
Fig. 4 Discriminant Analysis VIP Scores, ROC Curves, and Hierarchical Clustering Analysis of 7 Differential Metabolites among 5 Groups. (a) Discriminant analysis VIP score plot of the selected differential metabolites; (b) ROC curves. The vertical axis represents sensitivity (true positive rate), and the horizontal axis represents 1-specificity (false positive rate). Each line represents a specific metabolite; (c) Hierarchical clustering analysis of the 7 differential metabolites among the Recurrence Group, Preoperative Group, Three-month Postoperative Group, Six-month Postoperative Group, and Healthy Control Group. Red color indicates metabolites with higher peak intensities, deep blue color represents metabolites with lower peak intensities, and light blue color indicates metabolites with zero peak intensities. The color intensity corresponds to the peak intensity of the metabolites. The right side of the figure displays the mass-to-charge ratios of each metabolite, while the left and upper dendrograms represent the clustering results of the differential metabolites. The bottom part of the figure shows the sample numbers
Fig. 4 Discriminant Analysis VIP Scores, ROC Curves, and Hierarchical Clustering Analysis of 7 Differential Metabolites among 5 Groups. (a) Discriminant analysis VIP score plot of the selected differential metabolites; (b) ROC curves. The vertical axis represents sensitivity (true positive rate), and the horizontal axis represents 1-specificity (false positive rate). Each line represents a specific metabolite; (c) Hierarchical clustering analysis of the 7 differential metabolites among the Recurrence Group, Preoperative Group, Three-month Postoperative Group, Six-month Postoperative Group, and Healthy Control Group. Red color indicates metabolites with higher peak intensities, deep blue color represents metabolites with lower peak intensities, and light blue color indicates metabolites with zero peak intensities. The color intensity corresponds to the peak intensity of the metabolites. The right side of the figure displays the mass-to-charge ratios of each metabolite, while the left and upper dendrograms represent the clustering results of the differential metabolites. The bottom part of the figure shows the sample numbersCC BY · PubMed Central
Fig. 5 Mean Plots of 7 Differential Metabolites Among Five Groups. The plots depict the mean abundance of 7 differential metabolites among the five groups: Recurrence Group, Preoperative Group, Three-month Postoperative Group, Six-month Postoperative Group, and Healthy Control Group. The y-axis represents the relative abundance of the metabolites, while the x-axis shows the different groups. Panels (a) to (g) represent the following metabolites: (a) Lysophosphatidic acids; (b) Triglycerides; (c) Lysine; (d) Sphingosine-1-phosphate; (e) Phosphatidylcholine; (f) Oxidized Ceramide and (g) Phosphatidylglycerol
Fig. 5 Mean Plots of 7 Differential Metabolites Among Five Groups. The plots depict the mean abundance of 7 differential metabolites among the five groups: Recurrence Group, Preoperative Group, Three-month Postoperative Group, Six-month Postoperative Group, and Healthy Control Group. The y-axis represents the relative abundance of the metabolites, while the x-axis shows the different groups. Panels (a) to (g) represent the following metabolites: (a) Lysophosphatidic acids; (b) Triglycerides; (c) Lysine; (d) Sphingosine-1-phosphate; (e) Phosphatidylcholine; (f) Oxidized Ceramide and (g) PhosphatidylglycerolCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 8

Metadata

Authors
Qu, T., Zhang, S., Yang, S., Li, S., & Wang, D.
Affiliations
First Hospital of Jilin University (CN)
Corresponding author
Wang, Daguang
Venue
BMC Cancer
Published
2024-01-02
Volume
24
Issue
1
Pages
27-27
ISSN
1471-2407 (ISSN-L)
OpenAlex
W4390510150
Cited by
8
References
33
Citations by year
2026: 2 · 2025: 4 · 2024: 2
FWCI
1.09
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Major Research Program of the National Natural Science Foundation of China (91959201)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
gastric cancer, serum metabolomics, tumor recurrence monitoring, biomarkers, lysophosphatidic acid, triglycerides, lysine, sphingosine-1-phosphate, phosphatidylcholine, phosphatidylglycerol, differential metabolites, PLS-DA, hierarchical clustering
MeSH terms
Ceramides, Humans, Lysine, Lysophospholipids, Neoplasm Recurrence, Local, Phosphatidylcholines, Phosphatidylglycerols, Sphingosine, Stomach Neoplasms, Triglycerides, Metabolomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients. https://app.cochat.ai/papers/10.1186/s12885-023-11786-2
The paper
Qu, T., Zhang, S., Yang, S., Li, S., & Wang, D. (2024). Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients. BMC Cancer. https://doi.org/10.1186/s12885-023-11786-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.